Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
- L. Cubeddu, I. Hoffmann, N. Fuenmayor, A. Finn
- The New England journal of medicine
- 22 March 1990
It is suggested that cisplatin treatment increases the release of serotonin from enterochromaffin cells, and that ondansetron acts by blocking S3 receptors for serotonin. Expand
Effect of dose and food on the bioavailability of cefuroxime axetil.
There was a linear relationship between the fed dose and both the area under the plasma concentration time curve and the peak plasma concentration and a comparison of the AUC for the oral and intravenous data revealed that absorption is an apparent zero order process from 0.5 to 3 h after dosing. Expand
Formulation Selection and Pharmacokinetic Comparison of Fentanyl Buccal Soluble Film with Oral Transmucosal Fentanyl Citrate
A randomized, open-label, single-dose, four-period, Latin-square crossover study to understand the differences in the pharmaco-kinetics of fentanyl from FBSF compared with that of oral transmucosal fentanyl citrate (OTFC). Expand
Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine
- L. Webster, D. Gruener, Todd Kirby, Q. Xiang, E. Tzanis, A. Finn
- Pain medicine
- 24 February 2016
Chronic pain patients treated with around-the-clock full μ-opioid agonist therapy can be switched to buccal buprenorphine at approximately 50% of their full dose without an increased risk of opioid withdrawal or loss of pain control. Expand
Bioavailability and Metabolism of Prochlorperazine Administered via the Buccal and Oral Delivery Route
It is demonstrated that buccal administration of prochlorperazine produces plasma concentrations more than twice as high as an oral tablet, with less than half the variability, which should enhance the therapeutic role of pro chlorperazine in preventing and treating nausea and vomiting. Expand
Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study
- R. Rauck, J. North, L. Gever, I. Tagarro, A. Finn
- Annals of oncology : official journal of the…
- 25 November 2009
FBSF was well tolerated in the oral cavity, with no reports of treatment-related oral AEs, and is an effective option for control of breakthrough pain in patients receiving ongoing opioid therapy. Expand
In‐vitro characterization of the metabolism of prochlorperazine
Prochlorperazine (PCZ) is an antiemetic widely used in the management of nausea and vomiting. PCZ is reported to be extensively metabolized via the CYP450 system. However, the specific CYP450… Expand
Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
- L. Cubeddu, I. S. Hoffman, N. Fuenmayor, A. Finn
- Journal of clinical oncology : official journal…
- 1 October 1990
The results suggest that serotonin S3 receptor antagonists represent a novel, effective, and safe mode of therapy for nausea and emesis induced by cyclophosphamide-containing chemotherapies, and are compatible with the view that serotonin, acting on S3 receptors, mediates the nausea andEmesis occurring after cycloph phosphate chemotherapy. Expand
Lignocaine disposition in blood in epilepsy.
- P. Routledge, W. Stargel, A. Finn, A. Barchowsky, D. Shand
- British journal of clinical pharmacology
- 1 November 1981
Increased AAG concentration was associated with enhanced lignocaine binding in the plasma of epileptics, which may result in lower free (unbound) plasma concentrations of the drug compared to normal subjects with equivalent total plasma lignOCaine concentrations. Expand
Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain
These findings demonstrate the efficacy and tolerability of BBUP among opioid-naive patients requiring around-the-clock opioid treatment for CLBP. Expand